A two-dose series of the Pfizer-BioNTech COVID-19 vaccine was 100% effective against COVID-19 in 12-15 year olds more than four months after the second dose in the companies’ phase 3 clinical trial, Pfizer and BioNTech announced yesterday. The adverse event profile was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose, the companies said. They plan to submit the updated data to the Food and Drug Administration, which in May expanded the vaccine’s emergency use authorization to include 12-15 year olds. 

Related News Articles

Headline
The Centers for Disease Control and Prevention today released updated guidance for clinicians treating COVID-19 in patients who received the Pfizer COVID-19…
Headline
Pfizer’s COVID-19 vaccine booster for children under age 5 was 80.3% effective and well tolerated in a clinical trial involving 1,678 children who received the…
Headline
The Centers for Disease Control and Prevention yesterday recommended children age 5-11 receive a booster dose five months after completing the Pfizer COVID-19…
Headline
Learn how Loyola University Health System’s pop-up COVID-19 testing laboratory broadened collaboration between clinicians and hospital leadership, improved…
Headline
The Biden Administration plans to continue the COVID-19 public health emergency beyond July 15, administration officials told CNN this week. The…
Headline
U.S. residents can order online eight more free at-home tests for COVID-19, the White House announced yesterday. People who have difficulty accessing the…